AstraZeneca is seeking to add an additional $1 billion to its share buy-back program this year, Financial Times reports. The share repurchases could increase to $5 billion, from $4 billion in 2011.

The company is planning to use the entire proceeds from the sale of Astra Tech, a Swedish dental implants and medical devices maker, for share repurchases. It sold Astra Tech to Dentsply International for $1.8 billion in cash.

Click here for the story from Financial Times.

Click here for additional coverage from Reuters.